1	Effectiveness of the air-filled technique to reduce the dead space
2	in syringes and needles during ChAdox1-n CoV vaccine administration
3	
4	
5	¶ Patchara Phankavong <sup>1*</sup> , ¶ Naphatthorn Prueksaanantakal <sup>2</sup> , ¶ Nontawat Benjakul <sup>1</sup> , ¶ Anan
6	Manomaipiboon <sup>1</sup>
7	
8	
9	<sup>1</sup> Faculty of Medicine, Vajira Hospital, Navamindradhiraj University
10	<sup>2</sup> Kuakarun Faculty of Nursing, Navamindradhiraj University
11	
12	Short Title: Air-Filled Technique for ChAdox1-n CoV Vaccine Administration
10	
13	
14	Corresponding Author:
15	Email: patchara@nmu.ac.th
16	¶ These authors contributed equally to this work.
17 19	
18 19	
20	
21	
22 23	
24	
25	
26	
27 28	
28 29	
30	
31	NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.


2

# 32 Abstract

33	In the current study, we calculated the vaccine volume and amount of dead space in a
34	syringe and needle during ChAdox1-n CoV vaccine administration using the air-filled technique, to
35	reduce dead space in syringe and needle that administer up to 12 doses per vial. The hypothetical
36	situation uses a vial with a similar size as the ChAdox1-n CoV vial. We used distilled water (6.5 ml),
37	to fill the same volume as five vials of ChAdox1-n CoV. When 0.48 ml of distilled water is drawn
38	according to the number on the side of the barrel, an additional 0.10 ml of air can be used in the dead
39	space of the distilled water in the syringe and needle for 60 doses, which can be divided into an
40	average of 0.5 ml dose. ChAdox1-n CoV was administered using a 1-mL syringe and 25G needle to
41	administer ChAdox1-n CoV vaccine into 12 doses using this air-filled technique. The volume of the
42	recipient vaccine will be increase by 20% and save the budget of a low dead space syringe (LDS).
43	Keywords: Air-filled technique, ChAdox1-n CoV vaccine, COVID-19, Low dead space
44	syringe,
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	

3

## 58 Graphical Abstract



4

# 77 Introduction

Since December 2019, the SARS-CoV-2 virus epidemic has spread worldwide, leading to the declaration of a pandemic in March 2021[1]. Several countries have endeavored to experiment and create vaccines to prevent and control the transmission of COVID-19 [2]. The main vaccines in Thailand is ChAdox1-n.CoV, which has been approved by the Ministry of Public Health and the Food and Drug Administration. This vaccine was registered on January 20, 2021. However, the limited capacity and vaccination demand of every country has increased beyond supply, creating a shortage of vaccines in most countries, including Thailand.

85 ChAdox1-n.CoV is used to enhance immunity among people  $\ge 18$  years of age to prevent 86 symptoms of COVID-19 [3]. This vaccine is a monovalent vaccine consisting of adenovirus from 87 chimpanzees (ChAdOx1) encrypted by the glycoprotein S of SARS-CoV-2 [4]. After injection, the 88 glycoprotein S of SARS-CoV-2 strengthens the immune system and prepares them for later 89 infection.

A vial of ChAdox1-n.CoV can be divided into ten doses (multiple doses) of 5 ml for ten 90 people. The manufacturers generally overfill the vial to replace the dead space in the syringe and 91 needle in the preparation and injection procedure for ten people. The amount of overfilled vaccine is 92 the same in every brand for multiple dose vials, including Pfizer, which has sufficient vaccines for 93 six people. Therefore, in many countries that have reserved COVID-19 vaccines, the multiple dose 94 95 type is assigned to use an low dead space (LDS) syringes and needles to reduce the wasted volume 96 that remains in the tip of the syringes and needles [5]. However, the LDS and needle cost is 4 to 10 times more than a 1-ml syringe and 25G needle (1 to 1.5-inch length). Therefore the latter syringes 97 and needle needles are commonly used. Additionally, no manufacturers for LDS and needles are 98 99 available in Thailand, and they need to be imported from overseas. Moreover, there is a worldwide shortage of vaccines. Therefore, a study about vaccine administration, including the preparation and 100 101 injection procedure of ChAdox1-n.CoV, to allow the vaccine to be divided to 12 doses per vial

102	instead of 10, as limited by the manufacturer, is required. This procedure will help clinics suitably	
103	administer the vaccine in the most efficient manner, which will mitigate the supply issues and	
104	unavailability of LDS needles in many countries [6].	
105		
106	Materials and Methods	
107	This research was approved by the Ethics Committee at our hospital, registration no.	
108	096/2564.All procedures were performed after written informed consent from all participants.	
109	The research procedure was as follows:	
110	• The test was first performed using distilled water to test the hypothetical situation.	
111	• A vial with a similar size as the ChAdox1-n CoV vial was used. Distilled water of the	
112	same volume as a single vial of ChAdox1-n CoV(6.5 ml) was filled in the vial.	
113	• A digital precision balance weighing scale was prepared to measure empty syringes and	
114	vaccine (in mg) up to four decimal places and pass the calibration of National Institute of Metrology	
115	Thailand (NIMT) as described below.	
116	Step 1: 60 sets of 1-ml syringe and 25G needle were weighed and recorded, with a length of	
117	1 inch needle, and the weighted average was calculated.	
118	Step 2: 0.45 ml water with 0.1 ml air was aspirated, resulting in $< 0.5$ ml water being	
119	ejected from the syringe.	
120	Step 3: 0.48 ml of distilled water and an additional 0.10 ml of air was drawn into the syringe	
121	to reduce the dead space in the syringe and needle. The amount of the water appeared to be slightly	
122	more than 0.5 ml. Thereafter, the weight of 60 sets of syringe and needle were recorded and	
123	weighted average was calculated.	
124	Step 4: 0.5 ml of distilled water from the barrel was discarded, syringe and needle were	
125	weighed, the weight recorded,, and the weighted average calculated.	

6

• The experiment using the same procedures was repeated until 12 doses of distilled water 126 were obtained per vial, for which the amount in every dose was  $\geq 0.5$  ml. 127 • The second stage involved using ChAdox1-n CoV in the real situation in the same way as 128 in the hypothetical situation as described below. 129 Step 1: Sixty sets of 1-ml syringes and 25G needles, with a length of 1 inch needle, were 130 weighed, the weight recorded, and the weighted average calculated. Five vials of vaccine were used. 131 132 Because a vial can be divided into 12 doses, five vials would comprise 60 doses. Step 2: The vaccine was prepared by stabbing the needle in the vaccine vial and drawing in 0.48 133 134 ml of vaccine and an additional 0.10 ml of air to reduce the dead space in the syringe and needle. The amount of the vaccine would appear to be equal to or slightly more than 0.5 ml. Thereafter, the 135 60 syringe and needle sets were weighed, the weight recorded, and the weighted average calculated. 136 137 Step 3: The vaccine was injected to the muscle of the vaccine recipient following the vaccine administration instructions composed by the Nursing Department of the Faculty of Medicine, 138 Vajira Hospital, Navamindradhiraj University. Thereafter, the 60 syringe and needle sets were 139 weighed, the weight recorded, and the weighted average calculated. 140 ChAdox1-n CoV Injection Technique 141 The vaccine injection using the same needles to draw vaccine from the same vial could 142 allow the diseases to spread easily, such as Hepatitis B, Hepatitis C, and human immunodeficiency 143 virus (HIV). Thus, the hospital and universal infectious control guidance precautions were strictly 144 145 adhered to the aseptic technique. The vaccine injection procedures are described below. 1. Medical personnel must wear a surgical mask, glasses, and face shield, and sanitize their 146 hands with hand sanitizer and wear suitable gloves. 147 2. The medical personnel and recipients receiving injection must be explained to put one of 148

their upper arms on the table or on the surface, which is not higher than shoulder level, and not flex their

150 shoulder and upper arm muscles during the injection.

7

3. The syringe should be checked if it contains is 0.5 ml of the vaccine as prescribed by Astra 151 Zeneca. The skin where the vaccine is to be injected is cleaned with 70% alcohol and left to dry. 152 4. Before injecting the vaccine, the syringe should be pointed at 90 degrees to let the air 153 154 flow to the top of the barrel. Flicking the finger lightly on the barrel helps the air bubble move to the top (the syringe should not be shaken). Next, needle should be inserted through the subcutaneous 155 layer to the muscle ensuring that the tip of the needle is not in the blood vessel, and inject the vaccine 156 by pushing the plunger to the end. The air on the top part of the syringe pushes the dead space in the 157 syringe and needle to the muscle by a slight amount. Therefore, less than 1 mL air might pass to the 158 159 muscle, which does not cause any harm. If the medical personnel and recipients receiving injection have a thick subcutaneous layer, a 1.5-length 25G needle should be used instead. 160 5. the needle should be pulled out from the vaccine recipient and removed in the needle 161 162 clipping devices without using the luer lock. The syringe and all other equipment used should be 163 discarded in the infectious waste disposal container. 6. Finally a band-aid should be placed on the injection wound and the vaccine recipient 164 should be asked to wait in the waiting area to observe whether any symptoms occur after the 165 injection. 166 The researcher should check the specific gravity in the five vials of the ChAdox1-n CoV 167 used in the experiment to calculate the volume that the patient has received. 168 169 170 **Statistical Analysis** The data was analyzed using SPSS Program, Version 28 (Chulalongkorn University 171 Bangkok Thailand) to calculate the weighted average of the syringe, needle, vaccine, volume, and 172 standard variation. 173 174 175

8

#### 176

177

# 178 **Results**

In the experiment using 6.5 ml of the distilled water in the vial, having the same size as the ChAdox1-n CoV vial, 0.48 ml of distilled water and an additional 0.1 ml of air to replace the dead space of the distilled water in the syringe and needle was drawn. The distilled water was administered to 12 doses per vial. The weighted average in the syringe before injecting was evaluated to be 0.5168 ml, the weighted average of dead space 0.0122 ml, and the volume of distilled water injected out of the syringe 0.5046 ml.

The ChAdox1-n CoV vaccine administration experiment used a normal syringe and needle 185 to draw in 0.48 ml of the vaccine, according to the number on the side of the barrel and an additional 186 187 0.10 ml of air to reduce the dead space in the syringe and needle. We then used this procedure to prepare 0.5 mL or slightly more of ChAdox1-n CoV vaccine using a 1-ml syringe and 25G needle to 188 draw in the 0.48 ml of the vaccine, according to the number on the side of the barrel, and an 189 additional 0.10 ml of air to reduce the dead space in the syringe and needle x. We could administer 190 12 doses per vial. The weighted average of the vaccine before injecting was found to be 0.5048 ml 191 and the weighted average of the dead space 0.0263 ml. Thus, the volume of the vaccine that the 192 recipient would receive was 0.5048 ml (the weight of the vaccine that the recipient would receive 193 was = 0.5199/1.030 [sp.gr. of the vaccine]) 194

195

### 196 **Discussion**

This experiment was aligned with research on antibody level for SARS-CoV-2 after injection of the 1<sup>st</sup> dose of ChAdox1- n CoV-19 using 12 doses per vial [8]. We found that approximately 8.57 weeks after injecting 12 doses per vial, the level of immunity was higher at a positive value of 93.3%, and higher among women than men. Additionally, the immunity did not

9

201 vary according to age, disease, body mass index, blood type, and blood pressure, and corresponded with the advice from the Pfizer-BioNTech COVID-19 Vaccine, which uses LDS to divide six doses 202 203 of vaccine per vial. After injecting the vaccine to the recipient, we found  $\leq 0.035$  ml dead space in the syringe. From this experiment using the air-filled technique to reduce the dead space in the syringe 204 and needle, 0.0263 ml of the vaccine remained. Thus, the vaccine recipient will receive 0.5048 mL 205 volume of the vaccine using the 1-ml syringe and 25G needle instead of the LDS. This technique will 206 207 reduce the expenses of importing LDS, which costs 2.78 THB per syringe compared to 1.65 THB for a 1 ml syringe and 0.43 THB for a 25G needle. This administrative technique increases the amount 208 209 of the recipient vaccine by 20% and is more economized than using LDS. This will help the Nursing Department of the Faculty of Medicine, Vajira Hospital to create guidelines and strategies to 210 administer the vaccine using the air-filled technique to reduce the dead space in the syringe and 211 212 needle, as well as to publish an interdisciplinary method in vaccine administration for all vaccine recipients. 213

214

### 215 Conclusion

ChAdox1-n CoV vaccine administration using a 1-ml syringe and 25G needle to draw in 216 0.48 ml of vaccine, according to the number on the side of the barrel, and an additional 0.10 ml air, 217 to reduce the dead space in the syringe and needle, to achieve an average volume of 0.5 ml (or 218 slightly more), allowed the vaccine to be administered at 12 doses per vial. The air-filled and vertical 219 220 injection techniques included flicking the finger lightly on the barrel to let the air flow to the top of the barrel. Then, the syringe was pointed at 90 degrees to pierce the muscle before pushing the 221 plunger to the end. The air on the top pushed the dead space at the tip of the syringe and needle. We 222 223 found that 0.0263 ml of dead space remained.

224

226	
227	
228	
229	Acknowledgment
230	We wish to thank Assoc. Prof Anayn Manomaipiboon, the chancellor of Navamindradhiraj
231	University for providing advice and ideas relating to all aspects of this research.
232	We wish to thank Dr. Nontawat Benjakul, MD, Faculty of Medicine, Vajira Hospital in
233	Anatomical Pathology, Navamindradhiraj University for his assistance with the writing of the
234	manuscript and for proofreading the final document.
235	We wish to thank Ms. Yupin Chalermchai, Ms. Pensiri Kaewkasikarn, Ms. Chantana
236	Jinawong, Ms. Warisa Jirawatin, and all the registered nurses and staff for their support.
237	
238	Author contributions
239	AM conceptualized the method, designed experimental protocols and validation tests; PP
240	and NP conducted the experiments; AM and PP conducted data analysis and visualization; and PP
241	and NB wrote the manuscript.
242	
243	Ethics committee approval
244	The experiment was performed in accordance with the principles of the Declaration of
245	Helsinki and Good Clinical Practice. This study was approved by the Vajira Institutional Review
246	Board, Faculty of Medicine, Vajira Hospital, Navamindradhiraj University. The vaccine used was
247	authorized by the Thai FDA and the Department of Medical Science (DMS).
248	
249	Conflict of Interest Statement
250	All the authors declare that they have no competing interests.

1	1
	т.

251	
252	Funding source
253	This work was supported by a grant from Navamindradhiraj University
254	
255	Data availability statement
256	All data used in the preparation of the manuscript are related to the previously published
257	article and can be found in the Mendeley Data repository: "ChAdOx1nCoV-19 vaccination,"
258	Mendeley Data, V1, doi: 10.17632/yjhssw33cw.1
259	
260	
261	
262	
263	
264	
265	
266	
267	
268	
269	
270	
271	
272	
273	
274	
275	

12

- 276
- 277
- 278
- 279 **References**
- 1. Bhattacharyya A, Seth A, Srivast N, Imeokparia M, Rai S. Coronavirus (COVID-19): A systematic
- review and meta-analysis to evaluate the significance of demographics and comorbidities. Res Sq. 2021; rs.
- 282 3.rs-144684. doi:10.21203/rs.3.rs-144684/v1
- 283 2. Chang J, Agliata J, Guarinieri M. COVID-19 Enacting a 'new normal' for people who use drugs.
- Int J Drug Policy. 2020;83:102832. doi:10.1016/j.drugpo.2020.102832
- 285 3. Garba B, Zakaria Z, Salihu MD, Bande F, Saidu B, Bala JA. Breaking the cycle of the COVID-19
- transmission: A challenge for Nigeria. J Glob Health. 2020;10(2):020309.
- doi:10.7189/jogh.10.020309
- 4. COVID-19 Vaccine Important Information about the AstraZeneca vaccine Vaxzevria 29 April
- 289 2021. Accessed on May 10 from https://www.hse.ie/eng/services/news/ newsfeatures/COVID19-
- 290 updates/COVID-19-vaccine-materials/important-information-about-COVID19-vaccine-
- astrazeneca.pdf
- 5. Hancock E, Ward Z, Ayres R, Neale J, Hussey D, Kesten JM, et al.. Detachable low dead space
- syringes for the prevention of hepatitis C among people who inject drugs in Bristol, UK: an

economic evaluation. Addiction. 2020;115(4):702-713. doi:10.1111/add.14849

- 6. Hasan T, Beardsley J, Marais BJ, Nguyen TA, Fox GJ. The implementation of mass-vaccination
- against SARS-CoV-2: A systematic review of existing strategies and guidelines. Vaccines
- 297 (Basel). 2021;9(4). doi:10.3390/vaccines9040326
- 298 7. Kesten JM, Ayres R, Neale J, Clark J, Vickerman P, Hickman M, et al.. Acceptability of low dead
- space syringes and implications for their introduction: A qualitative study in the West of England.
- 300 Int J Drug Policy. 2017;39:99-108. doi:10.1016/j.drugpo.2016.09.005

- 8. Manomaipiboon A,, Phumisantiphong U, Maneerit J et al., Immunogenicity of the ChAdOx1 nCoV-19
- vaccine against SARS-CoV-2 with 12- dose vial: an interim analysis.Vaccine. 2022; 40(4): 587-593.
- 303 https://doi.org/10.1016/j.vaccine.2021.12.023